Participants’ Preferences for BUP-NX or XR-NTX and Associations with Induction Success and Relapse Rates in the NIDA-CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)

Publication Type
Conference Paper
Year of Publication
2018
Authors
King, J.; May, J.; Salazar, D.; Hoehn, A.; Shmueli-Blumberg, D.; Novo, P.; Choi-Kuaea, Y.; Peavy, K.M.; Wiebe, R.; Lee, J.; Rotrosen, J.
Secondary
College on Problems of Drug Dependence (CPDD)
Date Published
06/2018
Location
Portland, OR
Publisher
College on Problems of Drug Dependence (CPDD)
Keywords
BUP-NX; Buprenorphine; Extended-release naltrexone; NIDA CTN-0051; opioid treatment; relapse; X:BOT; XR-NTX
Abstract
Medication preference may be important clinically and in research. Including a preference measure in clinical studies provides insight into participants’ perceptions of treatment and may shed light on induction success and other study outcomes. In clinical practice, medication preferences should be explored and taken into consideration when planning treatment.